Fortis Healthcare
- Market cap
- ₹ 54,357 Cr.
- P/E
- 53.8x
- P/B
- 5.54x
- 52-week range
- 704.95 – 1,067.7
- ROE
- 11%
- ROCE
- 13%
- Dividend yield
- 0.1%
- Debt / equity
- 0.35
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Fortis Healthcare Limited is an India-based integrated healthcare service provider. The Company is primarily engaged in the business of healthcare services. Its segment includes the Healthcare business and the Diagnostics business. The healthcare business includes inpatient and outpatient services, sale of medical and nonmedical items and management fees from hospitals. The diagnostic business includes pathology and radiology services. Its specialties include Cardiac sciences, Oncology, Neurosciences, Gastroenterology, Orthopedics, and others. The healthcare verticals of the Company primarily consist of day care specialty, diagnostics and tertiary and quaternary care. The Company has approximately 27 healthcare facilities in India, 4750 operational beds. It operates in India, United Arab Emirates, Nepal, and Sri Lanka.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Fortis Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)53.8 against a typical 48.9: pricier than most peers (1st = cheapest).22nd of 40
- Sales growth+17.4% against a typical +21.1% from a year earlier.21st of 34
- Profit growth+2.2% against a typical +13% from a year earlier.21st of 31
- Share price, 3 months−20.2% against a typical −10.9%.29th of 34
- Size₹ 54,357 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).5th of 36
Latest announcements
Exchange filings and their impact on the company.
- Fortis to invest Rs 1.85 cr for 26% of a Haryana captive solar SPV to cut power costs.
Fortis Hospotel, a wholly owned subsidiary of Fortis Healthcare, will acquire 26% of Clean Max Sau Private Limited, an SPV for a captive solar power project in Haryana. The cash investment is up to Rs 1.85 crore and is to be completed within 3 months. The project will supply renewable power for captive use to help meet green-energy needs and optimize energy costs.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA+ by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil AA+ | Stable | 9 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 9 Sep 2026 | Reaffirmed | Crisil AA+ | — | CRISIL | ₹ 1,975.98 Cr. | |
| 5 Jan 2026 | Reaffirmed | Crisil AA+ | — | CRISIL | ₹ 1,975.98 Cr. | |
| 1 Sep 2025 | ▲ Upgrade | Crisil AA+ | — | CRISIL | ₹ 1,975.98 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 6 Aug 2026 | Financial Results | To consider and approve the Un-audited financial results (standalone & Consolidated) for the quarter ended Jun 30, 2026 |
| 22 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and recommendation of Final Dividend for the year ended March 31, 2026. |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 11 Nov 2025 | Financial Results | To consider and approve the Un - Audited financial results for the period ended September 30, 2025 |
| 6 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and Alteration of rights of debenture holders/ matters affecting the rights and interests of debenture holders of the existing 1,55,000 (One lac and fifty-five thousand) listed, senior, secured, rated, redeemable Non-Convertible Debenture, each having a face value of INR 1,00,000/- (Indian Rupees One lac) and an aggregate value of up to INR 1550,00,00,000/- (Indian Rupees One Thousand Five Hundred and Fifty Crores only) |
| 20 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,770 | 1,680 | 1,786 | 1,859 | 1,988 | 1,928 | 2,007 | 2,167 | 2,331 | 2,265 | 2,365 | 2,545 |
| Expenses | 1,440 | 1,396 | 1,405 | 1,516 | 1,554 | 1,553 | 1,572 | 1,676 | 1,775 | 1,759 | 1,832 | 2,008 |
| Operating Profit | 330 | 284 | 381 | 343 | 435 | 375 | 435 | 491 | 556 | 506 | 532 | 537 |
| OPM % | 19% | 17% | 21% | 18% | 22% | 19% | 22% | 23% | 24% | 22% | 23% | 21% |
| Other Income | 18 | 19 | 17 | 14 | −42 | 47 | −29 | 31 | 50 | −34 | −2 | 28 |
| Interest | 32 | 33 | 35 | 35 | 36 | 45 | 68 | 70 | 75 | 86 | 84 | 80 |
| Depreciation | 84 | 87 | 92 | 91 | 95 | 97 | 102 | 101 | 106 | 120 | 122 | 122 |
| Profit before tax | 233 | 183 | 271 | 230 | 261 | 279 | 237 | 351 | 425 | 266 | 324 | 363 |
| Tax % | 21% | 27% | 25% | 24% | 26% | 9% | 21% | 24% | 23% | 26% | 16% | 25% |
| Net Profit | 184 | 134 | 203 | 174 | 193 | 254 | 188 | 267 | 329 | 197 | 271 | 273 |
| EPS in Rs | 2.3 | 1.78 | 2.37 | 2.2 | 2.34 | 3.28 | 2.44 | 3.45 | 4.26 | 2.57 | 3.52 | 3.53 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 8%
- 5 Years
- 18%
- 3 Years
- 13%
- TTM
- 18%
- 10 Years
- 60%
- 5 Years
- 64%
- 3 Years
- 27%
- TTM
- 16%
- 10 Years
- 17%
- 5 Years
- 27%
- 3 Years
- 41%
- TTM
- —
- 10 Years
- 5%
- 5 Years
- 9%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Fortis Healthcare | ₹ 759.50 | ₹ 54,357 Cr. | 53.8x | 5.5x | 11% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
| Global Health | ₹ 1,165.00 | ₹ 31,449 Cr. | 63.7x | 8.9x | 15.2% | 12.6% |
Management
- Ashutosh Raghuvanshi
- Chief Executive Officer, Managing Director, Executive Director
- Vivek Kumar Goyal
- Chief Financial Officer
- Satyendra Chauhan
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.